医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aroa Biosurgery Posts Maiden Profit as It Expands Sales Presence in U.S. and Global Markets

2019年09月11日 AM12:28
このエントリーをはてなブックマークに追加


 

AUCKLAND, New Zealand

Aroa Biosurgery has posted a modest profit for the FY18/19 year, a first for the Auckland-based, privately held tissue-regeneration company since its formation 10 years ago.

Chief Executive Brian Ward said the first-time push into profit would be welcome news for the company’s tight and supportive family of investors. It was achieved off the back of 118% revenue growth to NZ$24.2 million.

“We are delighted that after a number of years of investment in product development, regulatory approvals, manufacturing capacity, and more recently in a direct sales team in the United States, we have demonstrated that we can be profitable,” Mr Ward says.

“While this is a major milestone for Aroa Biosurgery we will continue to prioritise growth over profitability to make sure that we capture the opportunity in front of us,” he says.

The company manufactures biomaterials for tissue regeneration marketed under brands such as Endoform™ and Ovitex™ which are processed from sheep rumens and used in complex wounds and surgical soft tissue repair applications.

Aroa has invested around $50 million in the past decade. During this time, it has gained FDA approvals in the U.S. market, established a clean room manufacturing facility and grown a 110 strong R&D and manufacturing team.

It also recently bought back its global woundcare rights and established a 50% share in a U.S. based sales joint venture that sells Aroa’s wound products into major hospitals across the U.S. The JV, known as Appulse, has recently hired five more people to increase geographic and channel reach which brings the total field sales team to thirty people. This month, Aroa opened a new office in San Diego adding a further five people in sales support.

“Our products have now been used in well over five million applications in the U.S. for complex wounds and soft tissue surgery. With a growing weight of supporting clinical evidence, we are very well placed to scale up in what is globally a $5 billion per annum, addressable market,” he says.

Aroa is beginning to pursue incremental growth from outside the United States. In the last year alone, the company has seen rapid growth off a low base in Germany, Austria, Thailand, Canada, Jordan, India and South America, and has further distribution agreements in the pipeline.

Mr Ward says the company is a passionate believer in ongoing product development. There is strong pipeline which will lead to new products in each of the next three years to leverage Aroa’s established market position.

“Aroa’s commitment to ongoing investment in R&D, quality, manufacturing and sales demonstrates our commitment to growth and to building a strong, long-term position in the regenerative tissue market,” Mr Ward says.

About Aroa Biosurgery:

Aroa headquartered in Auckland, New Zealand is a private, venture-funded soft-tissue repair company that develops and manufactures medical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from their Endoform® platform, a novel extracellular matrix biomaterial and distributed in the United States by Appulse and Tela Bio. Aroa strives to improve patient outcomes and provide better healing, every day, everywhere for everybody. aroabio.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005853/en/

CONTACT

Piet de Jong

For Aroa Communications

+64 21 812 766

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Dr. Reddy’s Laboratories announces launch of Doxercalciferol Injection in the U.S. Market
  • 海外の専門家によれば、リヤドは持続可能な都市への道を進んでいる
  • Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress
  • Zymeworks在ESMO亚洲大会上宣布推进与百济神州的临床合作并公布ZW25用于治疗HER2呈阳性癌症患者的1期临床研究更新数据
  •  Phenomics Health Inc. 收购专利药物代谢组技术